zurück

Olaparib (re-assessment: ovarian, fallopian tube or primary peritoneal cancer, BRCA-mutated, FIGO stages III and IV, maintenance therapy)

 

Subject:

  • Active Substance: Olaparib
  • Name: Lynparza®
  • Therapeutic area: Ovarian, fallopian tube or primary peritoneal cancer
  • Pharmaceutical company: AstraZeneca GmbH

 

Time table:

  • Start: 01.04.2023
  • Final decision by G-BA: 21.09.2023

 

Final decision:

  • No additional benefit proved